...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Effectiveness of combinations of Ayurvedic drugs in alleviating drug toxicity and improving quality of life of cancer patients treated with chemotherapy
【24h】

Effectiveness of combinations of Ayurvedic drugs in alleviating drug toxicity and improving quality of life of cancer patients treated with chemotherapy

机译：阿育吠陀药物组合在减轻药物毒性和改善接受化疗的癌症患者的生活质量方面的有效性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: This study was conducted to assess the effectiveness of combinations of Ayurvedic drugs in alleviating the toxicity of chemotherapy and improving the quality of life of cancer patients. The following was the research question: Can Ayurvedic drugs be used to alleviate the side effects of chemotherapy and improve the quality of life of cancer patients?Method: Random patients with malignancies of different tissues, grades, and stages were divided into two groups according to their treatment modality. Group 1 consisted of 15 patients treated with six cycles of chemotherapy alone and who did not receive any Ayurvedic drugs (control group). Group 2 consisted of patients (divided into three arms) who received Ayurvedic drugs during chemotherapy and after chemotherapy. Nineteen patients in arm 1 received the Ayurvedic drugs Mauktikyukta Kamdudha (MKD) and Mauktikyukta Praval Panchamruta (MPP) along with a full course of chemotherapy. Fifteen patients in arm 2 received the same Ayurvedic treatment, but the treatment was started after completing the sixth cycle of chemotherapy. Eighteen patients in arm 3 received the Suvarnabhasmadi formulation (SBD) in addition to MKD and MPP after completing the sixth cycle of chemotherapy. Treatment was given for 16 weeks in all three arms. Patients from both groups were observed for a period of 6 months. The assessment criteria depended on Common Toxicity Criteria (CTC designed by NIH and NCI): haemogram; weight; physical examination including Quality of Life Questionnaire (QLQ designed by the European Organization of Research and Treatment of Cancer (EORTC)) for functional, symptom and global scores; and Karnofsky score for assessment of general well-being and activities of daily life. ECOG (Eastern Cooperation Oncology Group) score was also additionally included for assessment of symptoms.Results: From amongst the symptomatic criteria, there was significant improvement in all the three arms compared with the control group in nausea, loss of appetite, constipation, and fatigue. There was significant improvement in the Karnofsky score and global score of the QLQ, which in fact incorporate symptomatic criteria, general condition, functional ability and disease-related symptoms. These significant differences were observed in group 2 (arms 1, 2, 3) in comparison with group 1 (control), in spite of the fact that in arms 2 and 3, the Ayurvedic treatment was started after completion of chemotherapy. The haemogram did not show a significant difference between the control and the three arms of group 2.Conclusion: Adjunct treatment with herbo-mineral and metallic Ayurvedic drugs appears to have a significant effect on reducing the toxic side effects of chemotherapy drugs in cancer patients. Our preliminary data suggests that Ayurvedic treatment should be given simultaneously from the beginning of chemotherapy to have the desired effect. However, there is a need to extend this work by conducting a well-planned two-armed study on cancer patients with defined cancer sites with selected Ayurvedic drug combinations, and observing the patients for a longer period of time to confirm the effectiveness of Ayurvedic drugs in reducing the side effects of chemotherapy.
机译：目的：本研究旨在评估阿育吠陀药物组合在减轻化疗毒性和改善癌症患者生活质量方面的有效性。以下是研究的问题：阿育吠陀药物可用于减轻化疗的副作用并改善癌症患者的生活质量吗？方法：根据组织，等级和阶段不同将恶性肿瘤随机分为两组。他们的治疗方式。第一组包括15例患者，这些患者仅接受了六个化疗周期的化疗，并且未接受任何阿育吠陀药物治疗（对照组）。第2组由在化疗期间和化疗之后接受阿育吠陀药物的患者（分为三组）组成。第1手臂的19名患者接受了印度草药药物Mauktikyukta Kamdudha（MKD）和Mauktikyukta Praval Panchamruta（MPP）以及完整的化疗过程。第2组中有15名患者接受了相同的印度草药治疗，但在完成第六个化疗周期后才开始治疗。在完成第六个化疗周期后，除MKD和MPP外，第3组的18名患者还接受了Suvarnabhasmadi制剂（SBD）。三个组均接受了16周的治疗。观察两组患者的病情，为期6个月。评估标准取决于共同毒性标准（NIH和NCI设计的CTC）：重量;身体检查，包括功能，症状和总体评分的生活质量调查表（由欧洲癌症研究与治疗组织（EORTC）设计的QLQ）;和Karnofsky得分，用于评估总体幸福感和日常生活活动。结果：从症状标准来看，与对照组相比，三组患者的三组均较恶心，食欲不振，便秘和疲劳明显改善。 。 QLQ的Karnofsky评分和整体评分有显着提高，这些评分实际上包含了症状标准，一般状况，功能能力和疾病相关症状。与第1组（对照组）相比，第2组（第1、2、3组）观察到了这些显着差异，尽管在第2和第3组中，阿育吠陀治疗是在化疗完成后开始的。对照组和第二组的三个臂之间的血流图没有显示出显着差异。结论：矿物质矿物质和金属阿育吠陀药物的辅助治疗似乎在降低化疗药物对癌症患者的毒副作用方面具有显著作用。我们的初步数据表明，从化疗开始应同时给予阿育吠陀治疗，以达到理想的效果。但是，有必要通过一项精心计划的两臂研究，以选定的阿育吠陀药物组合对具有明确癌症部位的癌症患者进行一项计划周密的研究，并长时间观察患者以确认阿育吠陀药物的有效性，从而扩大这项工作的范围。在减少化疗的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号